Latest Commercialisation News

EVE Health Group’s subsidiary Nextract has inked a pivotal two-year agreement with TeleDocs Clinic, enabling nationwide online prescribing of its upcoming erectile dysfunction and dysmenorrhea products ahead of regulatory approval.

Tivan Limited has reported exceptional fluorite assay results from its Sandover Project, with grades reaching up to 91.4% CaF2 and a mineralised strike length now extending to 7 kilometres. The company is advancing towards a maiden drilling campaign scheduled for October 2025.

EMVision Medical Devices has secured a $5 million non-dilutive government grant to accelerate global commercialisation of its innovative First Responder portable brain scanner, aimed at revolutionising pre-hospital stroke and brain injury care.

Enlitic, Inc. has launched a A$10 million placement alongside an offer of 125 million unquoted options, aiming to fuel growth in its AI-driven healthcare technology business. The move underscores both funding ambitions and the complex risks tied to AI adoption and market dynamics.

Syntara Limited has unveiled encouraging interim Phase 2a data for SNT-5505, an add-on therapy targeting myelofibrosis patients with suboptimal response to ruxolitinib. The data highlight meaningful symptom relief and spleen volume reduction, positioning the drug as a potential game-changer in a challenging treatment landscape.

Control Bionics is on track for its strongest financial year yet, driven by robust US and Australian sales and promising global trials of its NeuroStrip® device.

HITIQ has partnered exclusively with Shock Doctor to launch the PROTEQT instrumented mouthguard, aiming to transform concussion management worldwide. The company also initiates a $2.92 million rights issue to fuel this ambitious rollout.

SSH Group has raised $2.75 million in a placement anchored by mining sector heavyweight Ross Stewart Norgard, aiming to accelerate its mining services expansion in Western Australia.

Brazilian Rare Earths has successfully produced high-purity mixed-rare-earth carbonate and uranium yellowcake from its Monte Alto Project, marking a key milestone in its integrated supply chain ambitions.

Nanoveu Limited has locked in a $500,000 funding guarantee through an options underwriting agreement, underpinning its push to commercialise cutting-edge semiconductor and 3D visualisation technologies.

EVE Health Group has launched a $1.5 million capital raise alongside the acquisition of biotech firm Nextract, aiming to expand its footprint in health and pharmaceutical products focused on erectile dysfunction and period pain.

Felix Gold Limited has launched field exploration and development at its Treasure Creek Antimony Project in Alaska, aiming for potential antimony concentrate production by late 2025. The company is progressing drilling, environmental studies, and engineering design to support a feasibility study and permitting.